Biotechnology is no longer distant science fiction; it’s already a growing force in both national security and local economies. It affects everything from how much you pay at the pharmacy to whether ...
Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...
Hosted on MSN
Biotech beat Nvidia in 2025. Can it do it again?
Get your coffee ready because it's biotech time. Let's talk about biotech approvals, Carl, and what's going on at the FDA, because it does seem as though things are a little bit, let's call it ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Introducing CPC Biotech - one brand uniting critical fluid management components New brand unites CPC’s Biopharma connector ...
The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Pick #5 is about a biotech by the name of Cytokinetics (CYTK). The reason why I believe that it is important ...
BioTechAnalyzer is a research and analytics platform focused on making complex FDA-related biotechnology information clear, accessible, and actionable for investors. The platform focuses on late-stage ...
The multipronged organization has a lab space on the working waterfront and an academy, the Gloucester Biotechnology Academy, ...
Slow rolling chaos at the FDA and its effects on drug approvals. How to think about risk when investing in biotech. A review of results from DNA researcher Twist Bioscience. Don't wait! Be sure to get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results